Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + R-CHOP/R2-CHOP in High-Risk DLBCL
NCT03003520Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Feb 2017
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 5
01
Overview
Phase 2, open-label trial of durvalumab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Percentage of Participants Who Achieved a Complete Response (CR) at the End of Induction Therapy. Started Feb 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03003520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003520.